Navigation Links
Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimer's
Date:6/3/2009

Tampa, Florida (June 2, 2009) --Researchers affiliated with Natura Therapeutics, Inc., Tampa, Florida, and the University of South Florida (USF) have jointly received a one-year, $110,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health's (NIH) National Center for Complementary and Alternative Medicine to continue studying TeaMem, a compound made from green tea.

TeaMem holds promise for preventing and treating Alzheimer's disease (AD), a disease that the Alzheimer's Association says today affects as many as 5.2 million Americans. The most recent grant follows two other NIH grants to develop and evaluate TeaMem -- a $160,000 grant for 2007-2008 and a $140,000 grant for 2008-2009. The research conducted under these three grants was also supported through matching funds from the Florida High Tech Corridor Matching Grants Research Program.

According to Jun Tan, M.D., Ph.D., a professor in the USF Department of Psychiatry and Behavioral Medicine, and one of the grant's principal investigators, the grant will be used to investigate the role of TeaMem in opposition to cleavage of the amyloid precursor protein protelysis (APP) into Abeta peptides and resultant cerebral amyloidosis, a process identified as a key feature in AD pathology.

"Our recent findings suggest that strategies that promote non-amyloidogenic/alpha-secretase APP processing may have significant potential for the treatment of AD," said Tan.

This SBIR grant, the most recent of three NIH grants, allows the continuing development of TeaMem and its evaluation in the test tube (in vitro). The latest grant provides for testing in vitro and in the body (in vivo) using mouse models to evaluate the effects of TeaMem.

Early tests will evaluate TeaMem in promoting non-amyloidogenic APP alpha-secretase proteolysis and then examine its therapeutic and preventive effects on AD pathology and cognitive impairment.

"We expect to clearly define this non-amyloidogenic mechanism and identify the potential molecular drug targets essential for formulating novel, effective treatments against AD," explained Cyndy D. Sanberg, Ph.D., senior vice president of Natura Therapeutics, Inc. and the other PI on the grant.

Tests, including cognitive tests, will use mouse models for oral administration of TeaMem to a prophylactic treatment group that will be compared to a second group with AD-like pathology. Groups will be compared for the effect of reducing AD-like pathology and behavioral impairment. The studies, said Tan, could lay the groundwork for AD clinical trials in humans in the near future.

In their 2008 report, the Alzheimer's Association (www.alz.org) noted that AD was the nation's sixth leading cause of death and predicts 10 million baby boomers will develop AD. The direct and indirect costs of AD exceed $148 billion annually, said the Association.


'/>"/>

Contact: Dr. Jun Tan
jtan@health.usf.edu
813-974-9326
University of South Florida Health
Source:Eurekalert

Related medicine news :

1. The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally
2. The First High Performance Sports Water - AquaHydrate - to Offer Ionic Minerals Through Exclusive Agreement With Natural Foods Pioneer, Trace Minerals Research
3. New Journal of Natural Medicine Launched This June, Promotes Natural Therapy
4. Chocolate Milks Natural Muscle Recovery Benefits Match or May Even Surpass a Specially Designed Carbohydrate Sports Drink
5. Buster Brands Launches Natural Alternatives to Acetaminophen Pain Killers
6. US Farms, Inc. Announces Membership to Natural Products Association
7. Sun Shower(TM) All Natural Super Blends Now Light N Healthy
8. Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair
9. Natural Alternatives International, Inc. Announces Fiscal 2009 Q3 Results
10. Super Lice Repelled by All-Natural Products First Ever Independent Study Shows
11. When Stomach Flu Strikes, Work With, Not Against, Body's Natural Defenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Excel ... Mike Finnegan to the position of Executive Vice President, Sales and Marketing. Finnegan ... technology, telehealth and medical device sales leadership. He has received industry recognition for ...
(Date:6/27/2017)... Philadelphia PA and London UK (PRWEB) , ... June 27, 2017 ... ... for applying to a clinical study is whether they can trust the sponsor to ... competitive, it is vital that sponsors and CROs establish payment strategies that encourage sites ...
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the cloud-based payment ... care industry’s hospitals and provider groups, has announced that it will now offer ... Health is a San Francisco health-finance startup that has launched a series of ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on ... efforts, Louisiana became the sixth state to pass legislation which ensures that children ... Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington ...
(Date:6/27/2017)... California (PRWEB) , ... June 27, 2017 , ... A ... has been projected to reach a staggering $6.81 billion by the year 2024 according ... rising at a faster rate than those made from titanium. Los Angeles area clinic ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the ... President of R&D and Head of Virology Kristin Bedard has ... the Northwest and Beyond meeting sponsored by Life Science ... from 8:30-10:30 AM PDT at the Agora Conference Center in ... Bedard will be joined by other leaders in infectious disease ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
Breaking Medicine Technology: